- Home
- VOR vs NXJ Comparison
VOR vs NXJ Comparison
Compare VOR & NXJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VOR | NXJ |
|---|---|---|
| Founded | 2015 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 562.6M | 503.5M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | VOR | NXJ |
|---|---|---|
| Price | $13.51 | $12.28 |
| Analyst Decision | Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $64.78 | N/A |
| AVG Volume (30 Days) | ★ 549.7K | 94.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.27% |
| EPS Growth | ★ 2.86 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.13 | $11.01 |
| 52 Week High | $49.95 | $12.90 |
Technical Indicators
Market Signals| Indicator | VOR | NXJ |
|---|---|---|
| Relative Strength Index (RSI) | 43.87 | 32.69 |
| Support Level | $11.27 | $11.24 |
| Resistance Level | $14.73 | $12.37 |
| Average True Range (ATR) | 1.16 | 0.08 |
| MACD | -0.17 | -0.03 |
| Stochastic Oscillator | 10.66 | 7.69 |
Price Performance
Historical ComparisonAbout VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
About NXJ Nuveen New Jersey Qualified Municipal Fund
Nuveen New Jersey Quality Municipal Income Fund is a closed-end investment management company. Its objective is to provide current income exempt from regular federal and New Jersey income tax and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued. The company invests a majority of its managed assets in securities rated, at the time of investment, investment grade or, if the bonds are unrated, are judged by the manager to be of comparable quality.